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LETTER TO THE EDITOR
Pretreatment serum CRP and response to interleukin 2
Sir - Broom et al. (1992) have reported an interesting obser-
vation on the inverse correlation between pretreatment serum
C-reactive protein (CRP) and response to interleukin 2 (IL-2)
in patients with metastatic colorectal cancer. We would like
to report a similar observation in metastatic renal carcinoma.
Serum CRP levels were measured the day before starting
therapy in 121 patients with metastatic renal carcinoma
treated with IL-2 between 1987 and 1991 and who were
evaluable for response. None of these patients had evidence
of infection at the time of sample. Three different IL-2-
containing regimens were used: 56 patients received con-
tinuous intravenous (i.v.) IL-2, 28 bolus i.v. IL-2 with
interferon alpha (IFN) and LAK cells and 37 subcutaneous
IL-2 and IFN (Blay et al., 1992). As previously reported,
serum CRP levels were highly correlated to serum IL-6 in
these patients (Blay et al., 1992).
Patients who experienced progressive disease after IL-2 had
significantly higher pretreatment CRP levels than other
patients (P<0.001, Table I). Only one of the 37 (3%)
patients with pretreatment serum CRP over 50 mg 1-1
achieved response to IL-2 compared with 20 of the 84 (24%)
remaining patients (two-tailed Fisher's exact test: P = 0.007).
These results demonstrate that pretreatment serum CRP
levels are inversely correlated to the response to IL-2 in
metastatic renal carcinoma.
These results indicate that serum CRP is inversely cor-
related to the response to IL-2 in two different tumour
models (Broom et al., 1992). Several interpretations could
account for these observations. The increase in serum CRP
could be related to the production of proinflammatory
cytokines by tumour cells, such as IL-6, and thus be an index
of tumour burden. However, no correlation between IL-6
and tumour mass was observed in patients with metastatic
renal cancer (Blay et al., 1992). Alternatively, serum CRP
could by itself interfere with the immunological mechanisms
involved in the anti-tumour activity of IL-2. CRP has been
reported to play an important role in the cytotoxic activity of
NK cells (Hamoudi & Baum, 1991). CRP is also involved in
the binding of complement to CD3+ cells in vivo in patients
receiving IL-2, a phenomenon that contributes to endothelial
injury during IL-2 treatment (Thijs et al., 1990; Vachino et
al., 1991). Conceivably, high levels of circulating CRP in
these patients before IL-2 administration could interfere with
the biological mechanisms responsible for the antineoplastic
activity of IL-2 in vivo.
The observation that baseline serum CRP is inversely cor-
related to response to IL-2 in different tumours has impor-
tant potential consequences for the selection of candidates
for IL-2 therapy. The exact role of CRP in these observa-
tions remains to be elucidated.
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Table I Pretreatment serum CRPlevels and clinical response to IL-2 inpatientswith
metastatic renal carcinoma
Patients with Patients with
CRP (mg I-') CRP<50 mg 1' CRP>50 mg 1'
median (s.e.m.) number (%) number (%)
Objective response 20 (6.5) 20 (24%) 1 (3%)
(n = 21)
Stable disease 19 (6.1) 32 (38%) 7 (19%)
(n = 39)
Progressive disease 44 (5.3)* 32 (38%) 29 (78%)
(n = 61)
Total 84 (100%) 37 (100%)
*Progressive disease vs others: Mann-Whitney U-test: P<0.001.
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